Long-term follow-up of patients of intrahepatic malignancies treated with Iodine-125 brachytherapy

Nag, Subir; DeHaan, Megan; Scruggs, Granger R.; Mayr, Nina A.; Martin, Edward W.

doi:10.1016/j.ijrobp.2005.08.029

Cited by 58 publications

(25 citation statements)

References 62 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, iodine-125 implantation is recommended for the treatment of larger tumors because of a higher risk of residual or recurrent tumor. In previous study, it was reported that the 1-, 3- and 5-year recurrence-free rates of the 125 I brachytherapy after resection of HCC were 94.12%, 76.42%, and 73.65%, and their overall survival rates were 94.12%, 73.53%, and 55.88%, respectively9, which was also similar to another study21. This may result from that a high-dose short radiation emitted by 125 I could be continuous within the the target tissues for a long half-life of 59.4 days, which would trigger tumor cell apoptosis and drop proliferation of tumor cells by gathering cells in the radiosensitive cell cycle phase (G2/M)2031.…”

Section: Discussionsupporting

confidence: 84%

See 1 more Smart Citation

Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients

Jiang

Deng

Tian³

et al. 2016

Sci Rep

View full text Add to dashboard Cite

This study aimed to compare the efficacy and safety of EUS-guided ethanol injection and 125I seed brachytherapy for malignant left-sided liver tumors which were difficult for trans-abdominal intervention. The study protocol was registered at Clinicaltrials.gov (NCT02816944). Twenty-six patients were consecutively and prospectively hospitalized for EUS-guided interventional treatment of refractory malignant left-sided liver tumors between June 2014 and June 2016. Liver masses were detected using EUS in 25 of 26 (96.2%) patients. EUS-guided interventional treatment was completed uneventfully in 23 of 26 (88.5%) patients using anhydrous ethanol injection (n = 10) or iodine-125 seed implantation (n = 13). Six months later, complete response was achieved in 15 of 23 (65.2%) patients and partial response in 8 of 23 (34.8%) patients. Patients with tumor residual have second-look EUS-guided interventional treatment (n = 5), radiotherapy (n = 2) or surgical resection (n = 1). Complete response was achieved after repeated interventional treatment in 3 of 5 patients who underwent second EUS-guided intervention; 2 patients required additional surgical resection but one succeed. No significant complications occurred. Therefore EUS-guided 125I seed brachytherapy is an effective and safe treatment modality for radical operation or promising palliative control of malignant left-sided liver tumors refractory to trans-abdominal intervention.

show abstract

Section: Discussionsupporting

confidence: 84%

“…In addition, a systematic review by searching from PubMed up to August 2016 was performed. The summary of 11 studies of ethanol ablation and 125 I brachytherapy of the hepatocellular carcinoma was presented in Table 2 121314151617 and Table 3 918192021.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients

Jiang

Deng

Tian³

et al. 2016

Sci Rep

View full text Add to dashboard Cite

show abstract

“…12,13,69–71 Results from two small, randomized studies indicate that biliary stenting with photodynamic therapy can prolong survival, compared to stent placement alone. 13,15,72 An increase in median survival from 3–6 months to 16–21 months was noted when photodynamic therapy was performed in addition to stenting.…”

Section: Ductal Cholangiocarcinomamentioning

confidence: 99%

Cholangiocarcinoma—controversies and challenges

Patel

2011

Nat Rev Gastroenterol Hepatol

305

257

View full text Add to dashboard Cite

Cholangiocarcinomas are a diverse group of tumors that are presumed to originate from the biliary tract epithelium either within the liver or the biliary tract. These cancers are often difficult to diagnose, their pathogenesis is poorly understood, and their dismal prognosis has resulted in a nihilistic approach to their management. The two major clinical phenotypes are intrahepatic, mass-forming tumors and large ductal tumors. Among the ductal cancers, lesions at the liver hilum are most prevalent. The risk factors, clinical presentation, natural history and management of these two types of cholangiocarcinoma are distinct. Efforts to improve outcomes for patients with these diseases are affected by several challenges to effective management. For example, designations based on anatomical characteristics have been inconsistently applied, which has confounded analysis of epidemiological trends and assessment of risk factors. The evaluation of therapeutic options, particularly systemic therapies, has been limited by a lack of appreciation of the different phenotypes. Controversies exist regarding the appropriate workup and choice of management approach. However, new and emerging tools for improved diagnosis, expanded indications for surgical approaches, an emerging role for locoregional and intrabiliary therapies and improved systemic therapies provide optimism and hope for improved outcomes in the future.

show abstract

“…Yorozu et al 38 reported that a permanent 125 I seed implantation treatment of prostate cancer is safe and efficient. Nag et al 39 found that 125 I brachytherapy was a safe and effective alternative to other locally ablative techniques, and that it can provide long-term local control. The overall 1-, 3-, and 5-year actuarial intrahepatic local control rates were 44%, 22%, and 22%, respectively.…”

Section: Discussionmentioning

confidence: 99%

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Xiang

Liu

et al. 2015

Medicine

View full text Add to dashboard Cite

To investigate the safety and effectiveness of computed tomography (CT)-guided 125I seed implantation for locally advanced nonsmall cell lung cancer (NSCLC) after progression of concurrent radiochemotherapy (CCRT).We reviewed 78 locally advanced NSCLC patients who had each one cycle of first-line CCRT but had progressive disease identified from January 2006 to February 2015 at our institution. A total of 37 patients with 44 lesions received CT-guided percutaneous 125I seed implantation and second-line chemotherapy (group A), while 41 with 41 lesions received second-line chemotherapy (group B).Patients in group A and B received a total of 37 and 41 first cycle of CCRT treatment. The median follow-up was 19 (range 3–36) months. After the second treatment, the total response rate (RR) in tumor response accounted for 63.6% in group A, which was significantly higher than that of group B (41.5%) (P = 0.033). The median progression-free survival time (PFST) was 8.00 ± 1.09 months and 5.00 ± 0.64 months in groups A and B (P = 0.011). The 1-, 2-, and 3-year overall survival (OS) rates for group A were 56.8%, 16.2%, and 2.7%, respectively. For group B, OS rates were 36.6%, 9.8%, and 2.4%, respectively. The median OS time was 14.00 ± 1.82 months and 10.00 ± 1.37 months for groups A and B, respectively (P = 0.059). Similar toxicity reactions were found in both groups. Tumor-related clinical symptoms were significantly reduced and the patients’ quality of life was obviously improved.CT-guided 125I seed implantation proved to be potentially beneficial in treating localized advanced NSCLC; it achieved good local control rates and relieved clinical symptoms without increasing side effects.

show abstract

Long-term follow-up of patients of intrahepatic malignancies treated with Iodine-125 brachytherapy

Cited by 58 publications

References 62 publications

Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients

Efficacy and safety of endoscopic ultrasonography-guided interventional treatment for refractory malignant left-sided liver tumors: a case series of 26 patients

Cholangiocarcinoma—controversies and challenges

125I Brachytherapy in Locally Advanced Nonsmall Cell Lung Cancer After Progression of Concurrent Radiochemotherapy

Contact Info

Product

Resources

About